Ganapati R, Naik S S, Shah M H, Shirsat L S, Gaitonde B B
Lepr India. 1976 Jul;48(3):238-43.
This presentation reports the results of a short clinical trial with DADDS in 23 patients of lepromatous leprosy. Injections of DADDS administered intramuscularly in a dose of 225 mg every 70 days produced clinical regression noticeable earliest at few week after the secondn injection. A fall in the morphological index from 5.0 to 0.6 was observed in patients who had received from 3 to 7 injections. Erythema nodosum leprosum was encountered in 7 cases, four of which had moderate to severe grades of reaction. It is advisible to discontinue further injection of DADDS if initial signs of ENL are noticed, which are likely to occur after the second injection. These ENL responded well to the usual line of antireaction treatment. DDS level in blood was found to be more than 10 ng/ml before the fresh administration of DADDS upto the seventh injection, representing the period of follow-up in this study.
本报告介绍了一项针对23例瘤型麻风患者使用二乙酰氨苯砜（DADDS）的短期临床试验结果。每70天肌肉注射225毫克DADDS，在第二次注射后几周最早出现明显的临床症状消退。接受3至7次注射的患者，形态学指数从5.0降至0.6。7例出现麻风结节性红斑，其中4例有中度至重度反应。如果发现有麻风结节性红斑的初始迹象（可能在第二次注射后出现），建议停止进一步注射DADDS。这些麻风结节性红斑对抗反应治疗的常规方法反应良好。在本研究的随访期间，直到第七次注射新的DADDS之前，发现血液中的氨苯砜水平超过10纳克/毫升。
